How Investors Are Reacting To Novanta (NOVT) Record Bookings And Acquisition‑Led Growth Strategy
Novanta Inc. reported first-quarter sales of US$257.71 million with flat net income year over year, while emphasizing acquisitions and manufacturing optimization as core strategies. The company highlighted record bookings and strong momentum in Robotics & Automation and Advanced Surgery, aiming to reduce cyclicality and trade sensitivity through a disciplined acquisition pipeline. Investors are evaluating how this focus on M&A and bookings will influence Novanta's growth trajectory and risk profile, especially as the company's near-term growth relies on successful acquisitions to offset slower organic trends and manage trade exposure.
Novanta Inc. $NOVT Shares Acquired by Handelsbanken Fonder AB
Handelsbanken Fonder AB significantly increased its stake in Novanta Inc. (NASDAQ:NOVT) by 92.1% during the fourth quarter, now owning 175,888 shares valued at $20.93 million. Other institutional investors like AQR Capital Management, Goldman Sachs Group Inc., and Jane Street Group LLC also adjusted their positions in the technology company. Despite some insider selling, the company's stock is currently trading up 4.1% and analysts maintain a "Hold" rating with a consensus target price of $173.00.
Novanta Inc stock (CA67000B1040): medical and industrial photonics specialist after latest earnings
Novanta Inc, a specialized technology company focusing on photonics, precision motion, and vision technologies for medical and industrial applications, recently reported its Q1 2024 earnings. The report provided insights into its revenue figures, profitability, and demand trends from its medical and industrial customer base. The company's business model relies on supplying critical components to OEMs, benefiting from long-term relationships and recurring demand while balancing continuous innovation.
A Look at Novanta Inc (NOVT) After 4.0% Gain -- GF Value $154.26 vs Price $153.60
Novanta Inc (NOVT) shares recently gained 4.0%, bringing its price to $153.60, slightly below its GF Value™ of $154.26, indicating it is fairly valued. The company exhibits strong profitability and valuation with a GF Score™ of 89/100, though its growth rating is moderate. Notably, insiders have sold $5.1 million worth of stock in the last three months, which warrants close attention from investors despite the otherwise solid fundamentals.
Novanta Inc stock (CA67000B1040): growth tech supplier after latest quarterly update
Novanta Inc, a specialized technology supplier, has released its latest quarterly figures and updated its outlook, drawing attention from US investors. The company focuses on photonics, vision, and precision motion components for medical and industrial markets, with its core business model centering on high-value subsystems rather than finished consumer products. While exposed to macroeconomic uncertainties and capital equipment spending cycles, Novanta's long-term growth is driven by its engagement in structural trends like minimally invasive surgery, diagnostics, and factory automation.
Novanta Exceeds Q1 2026 Revenue Estimates, Reports 10.4% Sales Growth - News and Statistics
Novanta, a provider of medicine and manufacturing technology, surpassed Wall Street's Q1 2026 revenue and non-GAAP profit estimates, reporting sales of $257.7 million, a 10.4% increase. The company attributed its strong performance to broad-based demand and robust bookings, particularly in Robotics & Automation and Advanced Surgery, and provided optimistic guidance for the remainder of the year supported by growth in AI-driven robotics and precision manufacturing.
Novanta amends credit agreement to add $200 million term loan facility
Novanta Inc. announced it has amended its Fourth Amended and Restated Credit Agreement to include a new $200 million delayed draw term loan facility. These loans will be available for borrowing for up to six months, maturing on June 27, 2030, with interest rates tied to market benchmarks and Novanta's leverage ratio. This amendment also resets the company's incremental capacity for term loans and revolving commitments, supporting its financial flexibility.
Novanta Inc stock (CA67000B1040): $200 million term loan boosts financial flexibility
Novanta Inc. has secured a new $200 million delayed draw term loan, maturing in 2030, to enhance its financial flexibility for growth initiatives in photonics and precision medicine. This expansion of its credit facilities allows Novanta to access funds over the coming months without immediately increasing net debt. The loan structure, linked to the company's leverage ratio, supports disciplined capital allocation for potential acquisitions, capacity expansion, or product development.
Earnings Beat: Novanta Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Novanta Inc. (NASDAQ:NOVT) saw its stock price rise by 14% after beating analyst forecasts for its first-quarter results, with an impressive 27% higher statutory profit of US$0.51 per share, despite revenues matching expectations. Analysts have increased their future earnings per share predictions and raised the consensus price target to US$172, reflecting a positive shift in sentiment. However, the company's revenue growth is expected to slow compared to its historical performance and industry peers.
Novanta Expands Credit Facilities with New Term Loan
Novanta Inc. (NOVT) has expanded its credit facilities by adding a $200 million delayed draw term loan facility, maturing in 2030, to its existing credit agreement. This amendment, which became effective on May 15, 2026, aims to enhance Novanta’s financial flexibility and resets incremental term and revolver capacity. Spark, TipRanks’ AI Analyst, rates NOVT as "Outperform" due to its strong technical momentum, solid financial foundation, and constructive earnings outlook, despite valuation concerns.
Novanta to Present at Jefferies Global Healthcare Conference on Thursday, June 4, 2026
Novanta Inc.'s Chief Financial Officer, Robert Buckley, is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 4, 2026, in New York, NY. Novanta is a leading global supplier of core technology solutions for medical and advanced industrial equipment manufacturers. The company's common shares are traded on Nasdaq under the ticker symbol "NOVT".
Novanta amends credit agreement to add $200 million term loan facility
Novanta Inc. announced an amendment to its credit agreement, establishing a new $200 million delayed draw term loan facility. These loans will be available for six months and mature on June 27, 2030, with interest rates tied to Novanta's consolidated leverage ratio. The company also recently reported a Q1 2026 revenue beat of $257.7 million, despite a slight miss on EPS.
Novanta (NASDAQ: NOVT) sets up $200M delayed draw term loan to 2030
Novanta Inc. (NASDAQ: NOVT) has amended its credit agreement to secure an additional $200 million in delayed draw term loan commitments, maturing on June 27, 2030. This facility offers funding flexibility, allowing the company to draw funds for up to six months after May 15, 2026. The interest rates are tied to Novanta's consolidated leverage ratio, utilizing either the Base Rate or SOFR/SONIA/EURIBOR.
Novanta Inc -Co And Units Enter Second Amendment To Credit Agreement On May 15, 2026 - SEC Filing
Novanta Inc. and its units announced that they have entered into a Second Amendment to their Credit Agreement on May 15, 2026. This information was disclosed in an SEC filing. The article is a brief news update from Reuters.
Novanta to Present at Baird 2026 Global Consumer, Technology & Services Conference on Wednesday, June 3, 2026
Novanta Inc. announced that Robert Buckley, Chief Financial Officer, will present at the Baird 2026 Global Consumer, Technology & Services Conference on Wednesday, June 3, 2026, in New York, NY. Novanta is a leading global supplier of core technology solutions for medical, life science, and advanced industrial equipment manufacturers. The company's common shares are traded on Nasdaq under the ticker symbol "NOVT."
Novanta Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Novanta Inc. recently exceeded earnings expectations, with its shares surging 14% to US$156 after its latest quarterly results. Analysts have updated their forecasts, maintaining revenue estimates but becoming more bullish on earnings per share for 2026, leading to a 9.2% increase in the consensus price target to US$172. Despite an anticipated slowdown in revenue growth compared to historical performance and industry peers, the significant EPS upgrade indicates improved sentiment around Novanta's future earnings potential.
Novanta forecasts $259M-$264M Q2 revenue as 2026 outlook rises to $1,040M-$1,055M
Novanta is projecting second-quarter revenue to be between $259 million and $264 million. The company has also raised its outlook for 2026, anticipating revenue in the range of $1,040 million to $1,055 million. This revised guidance indicates positive growth expectations for Novanta's financial performance.
[Form 4] NOVANTA INC Insider Trading Activity
Novanta Inc.'s CEO, Matthijs Glastra, reported selling 7,500 shares of common stock on May 12, 2026, as part of a pre-planned Rule 10b5-1 trading plan. The sales, totaling approximately $1.13 million, occurred at prices between $150 and $151.34 per share. Following these transactions, Glastra still holds significant direct and indirect shares in the company, with the filing noting the pre-established plan means the timing carries less weight regarding his current views on the stock.
Novanta : to Present at the William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026
Novanta Inc. announced that its Chair & Chief Executive Officer, Matthijs Glastra, is scheduled to present at the William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026, in Chicago, IL. Novanta is a global supplier of core technology solutions for medical, life science, and advanced industrial original equipment manufacturers. The company's presentation will highlight its role as a trusted technology partner in precision medicine, manufacturing, robotics, and advanced surgery.
Novanta (NASDAQ:NOVT) Price Target Raised to $173.00 at Robert W. Baird
Robert W. Baird has increased its price target for Novanta (NASDAQ:NOVT) to $173.00 from $144.00, reiterating an "outperform" rating, indicating a potential 8.68% upside. This adjustment follows Novanta's latest quarterly report, where the company surpassed both earnings and revenue expectations, posting EPS of $0.81 and revenue of $257.71 million. Despite some insider selling, institutional ownership in Novanta has risen to 98.35%, reflecting significant institutional interest.
Novanta Inc (NOVT) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amidst Geopolitical Challenges
Novanta Inc (NOVT) reported strong Q1 2026 results, with revenue growing 10% and bookings up 37%, driven by advancements in AI-driven robotics and automation. Despite these positive indicators, the company faced challenges including decreased gross margins due to higher freight and tariff costs, and a decline in U.S. sales from shifting customer production. Novanta is addressing these cost challenges with price adjustments and expects to neutralize tariff impacts by Q2.
NOVT Stock Jumps As Earnings Beat Fuels Growth Story
Novanta Inc. (NOVT) stock surged 13.72% after beating Q1 2026 earnings expectations, reporting 10% revenue growth and a 37% increase in bookings. The company also provided optimistic guidance for Q2 and full-year revenue. Despite a rich valuation and some insider selling, the strong fundamentals and positive market reaction indicate sustained investor confidence in its growth trajectory.
Novanta (NASDAQ: NOVT) affiliate files Rule 144; Matthijs Glastra sold 26,000 shares
Novanta, Inc. (NASDAQ: NOVT) has filed Rule 144 notices, detailing a proposed resale of 7,500 common shares by an affiliate associated with Merrill Private Wealth Management. Additionally, the filing reports that Matthijs Glastra previously sold 26,000 shares across four separate transactions in February, March, April, and May 2026, with proceeds reaching $1,087,500 for one sale. The report also lists several Restricted Stock Units granted to individuals between 2017 and 2020.
Novanta Jumps 9.2% Amid Sector-Wide Rally
Novanta Inc. surged 9.2% to $152.81 on Tuesday, May 12, 2026, driven by a broad sector-wide rally that also saw competitors like Zebra Technologies and Roper Technologies make significant gains. This increase, which pushed Novanta's market capitalization to $5.4 billion, was not due to specific company news but rather widespread investor enthusiasm within the scientific and technical instruments sector. The article suggests monitoring whether this momentum is sustainable and if fundamental catalysts emerge to support the coordinated rally.
Novanta Q1 2026 Earnings Call Transcript
Novanta Inc. reported strong first-quarter 2026 results with a 10% revenue increase, 3% organic growth, and an impressive 37% year-over-year bookings growth, indicating robust demand across all business segments. The company's adjusted EBITDA grew by 14%, and its operating cash flow surged by 63%. Novanta is strategically focusing on high-growth markets like AI-driven robotics and minimally invasive surgery, with new product revenue up 50% year-over-year, and confident in achieving mid-single-digit organic growth for the full year.
Earnings Flash (NOVT) Novanta Inc. Posts Q1 Adjusted EPS $0.81 per Share, vs. FactSet Est of $0.78
Novanta Inc. (NOVT) reported Q1 adjusted earnings per share of $0.81, surpassing FactSet's estimate of $0.78. The company's Q1 revenue was $257.7 million, exceeding the FactSet estimate of $253.4 million. Novanta also provided Q2 guidance, expecting revenue between $259.0 million and $264.0 million, and adjusted EPS between $0.81 and $0.86.
NOVANTA INC 1Q 2026: Revenue $257.7M, EPS $0.51— 10-Q Summary
NOVANTA INC (NOVT) reported Q1 2026 results with revenue reaching $257.7 million, a 10.4% increase year-over-year. Despite the revenue growth, net income remained nearly flat at $21.1 million, and diluted EPS declined to $0.51 from $0.59. The revenue growth was primarily driven by strong performance in the Medical and Automation segments, alongside new product introductions.
Novanta: Q1 Earnings Snapshot
Novanta Inc. reported first-quarter profit of $21.1 million, or 51 cents per share, with adjusted earnings of 81 cents per share, surpassing Wall Street expectations. The company also exceeded revenue forecasts, posting $257.7 million. Novanta provided optimistic guidance for the second quarter and the full fiscal year.
Novanta (NASDAQ: NOVT) grows Q1 2026 sales, boosts 2026 revenue and earnings outlook
Novanta Inc. (NASDAQ: NOVT) announced strong financial results for Q1 2026, with GAAP revenue increasing by 10.4% to $257.7 million and Adjusted diluted EPS rising to $0.81. The company also provided an optimistic outlook for both Q2 and the full year 2026, projecting higher revenues and Adjusted EBITDA and EPS, reflecting confidence in its key markets. Despite some pressure on GAAP operating income and EPS due to increased expenses, Novanta reported robust cash generation and a healthy net cash position.
Novanta Announces Financial Results for the First Quarter 2026
Novanta Inc. reported strong financial results for the first quarter of 2026, with GAAP Revenue increasing 10% to $258 million and Adjusted EBITDA growing 14% to $57 million. The company delivered excellent bookings with a 1.10 book-to-bill ratio and 3.1% organic revenue growth. Novanta also provided optimistic financial guidance for the second quarter and full year 2026, projecting continued organic revenue growth driven by strong momentum in key end markets.
Novanta: Q1 Earnings Snapshot
Novanta Inc. (NOVT) reported a first-quarter profit of $21.1 million, or 51 cents per share, which adjusted to 81 cents per share, surpassing Wall Street expectations of 78 cents. The company also exceeded revenue forecasts, posting $257.7 million against an expected $253.4 million. Novanta provided optimistic guidance for the second quarter and full fiscal year regarding both earnings and revenue.
Novanta: Q1 Earnings Snapshot
Novanta Inc. (NOVT) reported strong first-quarter results, with profits of $21.1 million and adjusted earnings of 81 cents per share, surpassing Wall Street expectations. The company also exceeded revenue forecasts, posting $257.7 million. Novanta provided optimistic guidance for the upcoming quarter and the full fiscal year.
Novanta in the spotlight: Can earnings signal growth turnaround?
Novanta Inc. (NASDAQ: NOVT) is reporting its first-quarter earnings, with analysts expecting growth in EPS and revenue year-over-year, despite a sequential decline. Investors are watching for signs of sustained organic growth after three challenging years and the impact of manufacturing regionalization. The company's strategic position in the expanding surgical robotics market and potential M&A activity are also key points of interest.
Novanta Earnings: What To Look For From NOVT
Novanta (NASDAQ: NOVT), a medicine and manufacturing technology provider, is set to announce earnings results this Monday after market close. The company missed analysts' revenue expectations last quarter, reporting $258.3 million, but the market anticipates an 8.6% year-on-year revenue growth for the upcoming quarter. Despite past misses, analysts have largely reconfirmed their estimates, and positive sentiment in the electronic components segment suggests a hopeful outlook.
Number of shareholders of Novanta Inc. - Tangible Equity – NASDAQ:NOVTU
This article provides a financial overview of Novanta Inc. (NASDAQ: NOVTU), focusing on its tangible equity shareholder information. It details the company's financial data, market performance, and other related financial metrics available on TradingView. The content primarily consists of section headers and data sources, with specific shareholder numbers intended to be displayed in a table format.
Global Photonics Company to Wind Down Washington Operations and Cut 80+ Jobs
Novanta Corporation's Synrad brand is closing its Mukilteo, Washington operations, resulting in 83 layoffs starting in July 2026. The company is relocating its Mukilteo laser equipment facility to an affiliate location in the United Kingdom. Novanta specializes in precision photonics, laser, robotics, automation, and motion-control solutions for medical, life science, and industrial OEMs.
Medical devices maker to close Mukilteo plant, move work out of US
Novanta, a medical devices maker, plans to close its 72,420-square-foot facility in Mukilteo, Washington, and relocate the work to the United Kingdom. This move will result in the layoff of 83 employees and is part of the company's strategy to reduce complexity and scale operations. The announcement was made by Neetish Basnet for the Puget Sound Business Journal.
NOVT Earning Date, Earning Analysis and Earning Prediction
This article provides an earnings analysis and prediction for Novanta Inc. (NOVT), detailing revenue and EPS estimates for upcoming quarters. It highlights current analyst forecasts, historical stock price reactions to earnings, and the correlation between forecast revisions and stock performance, suggesting potential buying opportunities. The article concludes with a positive sentiment based on strong Q4 2025 earnings call indicators and optimistic guidance.
Novanta (NOVT) CEO sells 6,500 shares in pre-set 10b5-1 trades
Novanta Inc.'s CEO, Matthijs Glastra, sold 6,500 shares of common stock on May 5, 2026, through open-market transactions facilitated by a pre-established Rule 10b5-1 trading plan. The sales occurred at weighted-average prices between $130.21 and $133.30 per share. Despite these sales, Glastra maintains significant holdings both directly and indirectly through an irrevocable trust.
6,500-share sale notice for Novanta (NASDAQ: NOVT) with recent insider tranches
Novanta, Inc. (NOVT) has filed a Form 144 indicating a proposed sale of 6,500 shares of common stock, valued at $845,000, via Merrill Private Wealth Management. This filing also details previous sales by Matthijs Glastra in early 2026, involving tranches of 6,500 and 7,500 shares. The Form 144 serves as a notice of contemplated sales by an affiliate and documents prior dispositions relevant to volume and holding-period analysis.
Novanta Inc. $NOVT Shares Sold by Vanguard Group Inc.
Vanguard Group Inc. reduced its stake in Novanta Inc. by 0.9% in the fourth quarter, selling 38,190 shares but still owning 12.13% of the company valued at approximately $516.5 million. Concurrently, Novanta's CFO Robert Buckley and CEO Matthijs Glastra also sold significant shares, contributing to over $3.29 million in insider sales over the last 90 days. Despite mixed analyst ratings, with an average "Hold" and a target price of $144, Novanta recently beat its quarterly EPS estimates and provided positive FY2026 EPS guidance.
Novanta (NOVT) Projected to Post Earnings on Monday
Novanta (NASDAQ: NOVT) is expected to announce its Q1 2026 earnings before market open on Monday, May 11th, with analysts projecting $0.77 EPS and $253.4 million in revenue. The company's corporate insiders have been net sellers, offloading shares worth approximately $3.30 million over the last 90 days. Despite this, institutional ownership remains high at 98.35%, and the stock currently holds an average analyst rating of "Hold" with a target price of $144.00.
Responsive Playbooks and the NOVT Inflection
This article analyzes Novanta Inc. (NASDAQ: NOVT), identifying a weak near-term sentiment while highlighting an exceptional 44.1:1 risk-reward setup. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and support/resistance levels for various holding periods.
Fenimore Asset Management Inc Buys Shares of 118,553 Novanta Inc. $NOVT
Fenimore Asset Management Inc. recently acquired 118,553 shares of Novanta Inc. (NASDAQ:NOVT), establishing a new stake valued at approximately $14.1 million. This comes as company insiders, including the CEO and CFO, have been net sellers of the stock. Despite a "Hold" consensus rating from analysts, Novanta exceeded Q4 EPS estimates and provided positive FY2026 guidance.
Novanta Inc. $NOVT is Conestoga Capital Advisors LLC's 9th Largest Position
Conestoga Capital Advisors LLC has increased its stake in Novanta Inc. (NASDAQ:NOVT) by 3.4%, making it their ninth-largest holding, valued at approximately $173.5 million. Despite Novanta beating Q4 EPS estimates, revenue was slightly below expectations, and the company issued FY2026 guidance with analysts projecting around $3.54 EPS. Noteworthy insider selling has occurred, yet institutional investors hold a dominant 98.35% of the stock.
Novanta Inc. $NOVT Stock Position Boosted by Universal Beteiligungs und Servicegesellschaft mbH
Universal Beteiligungs und Servicegesellschaft mbH significantly increased its stake in Novanta Inc. (NASDAQ:NOVT) during the fourth quarter. Several other institutional investors also adjusted their positions in the technology company. Analyst ratings for Novanta are mixed, with a consensus "Hold" rating and a target price of $144.00.
Vanguard Capital Management reports 1.89M Novanta shares (NASDAQ: NOVT)
Vanguard Capital Management has filed a Schedule 13G, disclosing beneficial ownership of 1,886,765 shares, representing 5.27% of Novanta Inc. (NOVT) common stock. The filing indicates Vanguard has sole dispositive power over all these shares but sole voting power over only 273,550 shares, with the ownership covering Vanguard-managed accounts, funds, and affiliates. This passive investment suggests significant institutional ownership without an intent to influence company control.
Novanta (NASDAQ:NOVT) Stock Price Crosses Above 50-Day Moving Average - Should You Sell?
Novanta (NASDAQ:NOVT) briefly traded above its 50-day moving average but then dropped, experiencing near-term volatility. Analysts generally hold a "Hold" rating with an average price target of $144, though recent activity includes both upgrades and downgrades. Insiders have been net sellers, while institutional ownership remains high, and the company issued FY2026 EPS guidance of $3.50-$3.65.
Novanta Inc (NOVT) Shares Fall 6.3% -- What GF Score of 92 Tells Investors
Novanta Inc (NOVT) shares recently fell 6.3% on April 29, 2026, despite an overall positive performance over the past year. The company is deemed significantly undervalued by GuruFocus's GF Value™ and holds a strong GF Score™ of 92/100, indicating good long-term potential. However, insider selling totaling $5.1 million over the last three months raises a note of caution for potential investors.
Vanguard Portfolio Management (NASDAQ: NOVT) reports 7.01% stake in Novanta
Vanguard Portfolio Management has reported a 7.01% passive stake in Novanta Inc. (NASDAQ: NOVT) through a Schedule 13G SEC filing. This filing indicates beneficial ownership of 2,508,270 shares of common stock as of March 31, 2026, with Vanguard possessing sole dispositive power over all these shares and sole voting power over 31,389 shares. The disclosure suggests an analyst-neutral stance and emphasizes that this passive investment is unlikely to solely drive future voting outcomes for Novanta.
